Literature DB >> 26579979

Phosphorus Removal in Low-Flux Hemodialysis, High-Flux Hemodialysis, and Hemodiafiltration.

František Švára1, František Lopot, Ivo Valkovský, Ondřej Pecha.   

Abstract

Phosphorus removal by hemoelimination procedure is a important mechanism to maintain phosphorus level in acceptable level in patients on dialysis. Phosphorus is removed by both diffusion and convection, but in clinical practice, it is not possible to differentiate the contribution of this two transport modalities. We used Gutzwiller formula to quantify the amount of removed phosphorus and compared it in low-flux hemodialysis (LFHD), high-flux hemodialysis (HFHD), and on-line hemodiafiltration (HDF). There were no significant differences in phosphorus predialysis concentration, duration of procedure, processed blood volume and ultrafiltration, e.g., factors, which could possibly influence phosphorus elimination. All three tested dialysis modes also did not differ in urea dialysis dose (Kt/V) as a parameter of small molecular weight removal (LFHD, 1.50 ± 0.04 vs HFHD, 1.5 ± 0.06 vs HDF, 1.5 ± 0.05). The amount of removed phosphorus in LFHD, HFHD, and HDF was 34.0 ± 1.2, 37.8 ± 1.6, and 38.3 ± 1.4 mmol, respectively. Statistically significant increase in phosphorus removal was seen only with use of high-flux membrane (HFHD and HDF) when compared with the low-flux one. No difference was, however, found between HFHD and HDF. It can thus be concluded that phosphorus removal in all three dialysis modes is a predominantly diffusive issue and contribution of convection to it is minor to negligible.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26579979     DOI: 10.1097/MAT.0000000000000313

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  6 in total

1.  Fibroblast Growth Factor 23 Trajectories in Chronic Hemodialysis Patients: Lessons from the HEMO Study.

Authors:  Anna Jovanovich; Zhiying You; Tamara Isakova; Kristen Nowak; Alfred Cheung; Myles Wolf; Michel Chonchol; Jessica Kendrick
Journal:  Am J Nephrol       Date:  2019-02-28       Impact factor: 3.754

2.  EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients.

Authors:  Kathleen M Hill Gallant; Elizabeth R Stremke; Laurie L Trevino; Ranjani N Moorthi; Simit Doshi; Meryl E Wastney; Nozomi Hisada; Jotaro Sato; Yoshitaka Ogita; Naohisa Fujii; Yuya Matsuda; Takei Kake; Sharon M Moe
Journal:  Kidney Int       Date:  2020-10-31       Impact factor: 10.612

3.  Aberrant cortical thickness in neurologically asymptomatic patients with end-stage renal disease.

Authors:  Jianwei Dong; Xiaofen Ma; Wuhong Lin; Mengchen Liu; Shishun Fu; Lihua Yang; Guihua Jiang
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-02       Impact factor: 2.570

4.  Phosphate clearance in peritoneal dialysis.

Authors:  Malgorzata Debowska; Rafael Gomez; Joyce Pinto; Jacek Waniewski; Bengt Lindholm
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

5.  Impact of High-Flux Hemodialysis on Chronic Inflammation, Antioxidant Capacity, Body Temperature, and Immune Function in Patients with Chronic Renal Failure.

Authors:  Sufang Li; Hongwei Li; Jun Wang; Lianliang Yin
Journal:  J Healthc Eng       Date:  2022-03-28       Impact factor: 2.682

6.  A comparative analysis of high-flux and low-flux dialysis in cervical cancer patients with obstructive renal failure showing no significantly improved renal function after catheterisation.

Authors:  Chen-Li Zhang; De-Qiong Xie; Li-Na Ao; Lei Zhu
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.